ClinicalTrials.gg
Not yet recruitingNCT06249243Updated Jul 30, 2024

Affection of Renal and Urinary System in IBD Patients

An observational study in Nephrolithiasis, Glomerulonephritis, Amyloidosis,AKI, CKD, Tubuli Interstitial and Urinary System Disorders in IBD Patients, sponsored by Assiut University. Not yet recruiting. Per ClinicalTrials.gov, last updated 2024-07-30.

Sponsored by Assiut University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
100
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies in Nephrolithiasis by Assiut University — 4 open to participants now, 4 under way, none of them phase 3. Nephrolithiasis · Assiut University.

Started
2024
with 2 others
Observational
6 of 10
2 open now
Registered
7th of 10
by date

Among the 10 studies in Nephrolithiasis by Assiut University, this one is one of 3 that started in 2024, is one of 6 observational ones, and was the 7th registered.

Nephrolithiasis

324 studies on the registry are indexed under Nephrolithiasis; 89 are open to participants now.

Browse Nephrolithiasis studies →

Open to participants now

4 of the 10 studies in Nephrolithiasis by Assiut University are open now. Recruiting first, the newest first:

All 4 open studies →

Where they have run

Who these studies take

Of the 51 Nephrolithiasis studies recruiting now, 30 (59%) set no upper age limit and 14 (27%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Nephrolithiasis by Assiut University, or all of them as a file.
02

Study summary

Detection and classification of different renal and urinary affection in patients with IBD that attended to Assist University Hospitals

Read the detailed description

Background (Research Question, Available Data from the literature, Current strategy for dealing with the problem, Rationale of the research that paves the way to the aim(s) of the work). (200-250 words max.) Inflammatory bowel disease is an idiopathic disease cause sever inflammation of GIT , presentes in ulcerative colitis or Crohn's disease occur in 6%-47%

IBD is profoundly associated with extra intestinal manifestions , Especially renal and urinary involvement occurs in 4% - 23% of patients with IBD.

Patterns of renal complications include nephrolithiasis, glomerulonephritis, amyloidosis, AKl, CKD, tubulointerstitial nephritis, asymptomatic proteinuria and hematuria; each type has specific mechanism

Nephrolithiasis is 10-100 times greater in IBD patients than general population.most common stones are calcium, oxalate and urate; Stones occur due to loss of electrolytes "Mg,k" due to diarrhea which lead to crystallization.

Glomerulonephritis pattern in IBD , is associated with IgA nephropathy, IgM nephropathy, membranous and focal segmental glomerulonephritis.

There is genetic connection between IgA nephropathy and intestinal diseases!

Secondary amyloidosis (AA-type) is a rare but serious complication of IBD.renal amyloidosis had been proven to be the most common lethal manifestion of IBD - associated amyloidosis (A), since renal involvement rapidly leads to end stage renal failure.

Sever long -standing IBD consists a predisposing factor for renal complications that occur in 4-23 % of patients So we aim to shed more light on the pathophysiology of renal damage in IBD; considering the renal manifestions and complications of IBD, it is important to emphasize the role of screening of renal function in preventing, diagnosing, and,if possible, reversing probable kidney damage.

03

Conditions studied

  • Nephrolithiasis, Glomerulonephritis, Amyloidosis,AKI, CKD, Tubuli Interstitial
  • Urinary System Disorders in IBD Patients
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Sample size was calculated by using it open -epi version 3 According to the prevalence of urinary affection in IBD patients 13,5%() Sample size was 92 patient at confidance level 95% +-7 confidance limit

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 100 patients suffering of IBD who attended to AUH either with Crohn's or ulcerative colitis with different presentation

Exclusion criteria

Exclusion Criteria:

  • Patients with other known cause of kidney or urinary affection as DM,HTN,APCKD, lupus nephritis,UTI.....
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
100 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Patterns of renal and urinary involvement in IBD patients

    Is renal and urinary system affect on IBD patients ?

    Time frame: 2 years

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2024; primary completion for Sep 2026, 25 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2023
First posted
Feb 8, 2024
StartEst.
Aug 20, 2024
Primary completionEst.
Sep 25, 2026
CompletionEst.
Oct 25, 2026
Last update
Jul 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06249243
Lead sponsor
Assiut University
Responsible party
Rania Essam Mohamed (Assistant Lecturer, Assiut University) — Principal investigator
First posted
Feb 8, 2024
Start date
Aug 20, 2024 (estimated)
Primary completion
Sep 25, 2026 (estimated)
Completion
Oct 25, 2026 (estimated)
Last update
Jul 30, 2024

Study contacts

Rania Essam, Researcher
Contact
re2677440@gmail.com
01285082769
Mohamed Hassan, Staff doctor
Contact
01030430421
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion